Imaging with 68Ga-PSFA in patients with specific cancer markers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the safety and effectiveness of a new imaging agent, 68Ga-PSFA, which targets both PSMA and FAP receptors in patients with suspected or diagnosed malignancies. The study aims to evaluate how well this dual receptor PET radiotracer can identify lesions in patients with PSMA/FAP positive diseases. Participants will undergo PET imaging to assess the biodistribution of the radiotracer and its potential utility in clinical diagnosis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. At least 18 years of age.
2. Signed informed consent.
3. Patients with suspected or newly diagnosed or previously malignant disease, with either PSMA or FAP positive expression (supporting evidence may include MRI, CT, and pathology report, etc).

Exclusion Criteria:

1. Patients with non-malignant disease.
2. Patients with pregnancy.
3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
4. Known or expected hypersensitivity to 68Ga-PSFA or any of its components.
5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.

Where it's running

• The First Affiliated Hospital of Chongqing Medical University
  Chongqing, Chongqing Municipality, China Recruiting

Study contacts

• Study coordinator: Xiaoyang Zhang, PhD
• Email: zhangxy@mail.bnu.edu.cn
• Phone: 86 023-89011755

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating PSMA PET/CT Imaging for Prostate Cancer Patients

  This study is testing a special type of imaging called PSMA PET/CT to see if it can help find cancer in adults who have or might have prostate cancer.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT06690970

• Imaging with a new PET agent for SSTR2 positive diseases

  This study is testing a new imaging agent to see if it can provide better results for patients with SSTR2 positive diseases compared to the current standard imaging method.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT05873777

• PD-L1 PET/CT to see primary and metastatic PD-L1-related lesions in adults

  This study tests whether 68Ga/18F-PD-L1 PET/CT can help detect primary and metastatic PD-L1-related tumors in adults.

  Recruiting at 3 sites Tianjin Medical University · Hefei, Anhui and 2 other locations · NCT07618936

• Classifying duodenal polyps in familial adenomatous polyposis

  This project will test two risk models to see if they better predict dangerous duodenal polyps and cancer risk in people with genetically confirmed FAP.

  Recruiting at 2 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan, MI and 1 other locations · NCT07199127

• FAPI-PET/CT imaging for diagnosing and staging pancreatic cancer

  This study will try 18F‑FAPI‑74 PET/CT scans in adults with suspected or recurrent pancreatic cancer to see if they detect lymph node spread and distant metastases more accurately.

  Recruiting Phase 2/3 Turku University Hospital · Turku · NCT07098598

• Establishing a cohort for Alzheimer's disease research in China

  This study is trying to understand how brain scans and other health markers relate to Alzheimer's disease in both people with and without cognitive issues in China, to help find ways to detect and prevent the disease early.

  Recruiting Huashan Hospital · Shanghai · NCT06827678

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.